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Abstract
Background: Multiple sclerosis (MS) is a complex trait in which alleles at or near the class II loci
HLA-DRB1 and HLA-DQB1 contribute significantly to genetic risk. The MHC class II transactivator
(MHC2TA) is the master controller of expression of class II genes, and methylation of the promoter
of this gene has been previously been shown to alter its function. In this study we sought to assess
whether or not methylation of the MHC2TA  promoter pIV could contribute to MS disease
aetiology.
Methods: In DNA from peripheral blood mononuclear cells from a sample of 50 monozygotic
disease discordant MS twins the MHC2TA promoter IV was sequenced and analysed by methylation
specific PCR.
Results: No methylation or sequence variation of the MHC2TA promoter pIV was found.
Conclusion: The results of this study cannot support the notion that methylation of the pIV
promoter of MHC2TA contributes to MS disease risk, although tissue and timing specific epigenetic
modifications cannot be ruled out.
Background
Genetic-epidemiological studies indicate unequivocally
that there is a genetic influence on susceptibility to Multi-
ple Sclerosis (MS) [1]. The only consistent genetic associ-
ation with MS in Northern Europeans had been with
extended MHC haplotypes especially those containing
HLA-DRB1*1501 [1]. Recently, the interleukin 7 receptor
(IL7R) and interleukin 2 receptor (IL2R) genes have been
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shown to be additional MS susceptibility loci [2,3]. How-
ever, any effect of IL7R or IL2R is small and it is clear that
the MHC is the key MS susceptibility locus [4].
The MS MHC class II association has been fine mapped to
the extended haplotype HLA-DQA1*0102-DQB1*0602-
DRB1*1501-DRB5*0101 [5]. Intense linkage disequilib-
rium within the MHC has prevented the exact susceptibil-
ity locus from being conclusively identified. Analysis of
the MHC region with a large number of markers as well as
classical typing show evidence for the involvement of the
class II region only [6,7]. However, the paradigm is more
complex than one in which the HLA-DRB1*15 allele acts
solely to increase MS risk. Our previous investigations
have shown that HLA-DRB1*15 and HLA-DRB1*17 bear-
ing haplotypes increase risk of MS, and HLA-DRB1*14
and  HLA-DRB1*11  bearing haplotypes are protective
[8,9]. Additionally, HLA-DRB1*10, DRB1*01 and
DRB1*08 interact with HLA-DRB1*15 to influence dis-
ease risk [8,9].
Given the unequivocal MHC class II association with MS,
the amount and cellular distribution of class II molecules
may therefore be important factors in determining suscep-
tibility to the disease. MHC class II molecule expression is
regulated primarily through a transcriptional co-activator
termed MHC2TA [10]. MHC2TA functions as a non-DNA-
binding co-activator that coordinates multiple events that
are required for the activation of transcription including
the recruitment of transcription factors and phosphoryla-
tion of RNA Polymerase II [11]. The highly regulated pat-
tern of expression of the gene encoding MHC2TA dictates
where, when and to what level MHC class II genes are
expressed [11]. Transcription of the gene encoding
MHC2TA is controlled by a large regulatory region that
contains three independent promoters (pI, pIII and pIV)
[11]. The promoter pIV is essential for driving MHC2TA
expression in cells that are sensitive to interferon-γ, and it
has been shown that methylation of CpG dinucleotides in
this promoter region can influence the expression of
MHC2TA and thus MHC class II molecules [12].
Given a contentious association of MHC2TA  polymor-
phisms with susceptibility to MS [13,14], we sought to
assess whether or not methylation of the MHC2TA pIV
promoter could contribute to MS aetiology using a cohort
of monozygotic discordant twins, potentially ideal for
entangling genetic and epigenetic contributions to disease
susceptibility.
Methods
Subjects
All subjects used in the study were ascertained through the
ongoing Canadian Collaborative Project on the Genetic
Susceptibility to MS (CCPGSMS), for which the method-
ology has been previously described [15,16]. Each partic-
ipating centre of the CCPGSMS obtained ethical approval
(as set out in the Helsinki Declaration) from the relevant
institutional review board, and the entire project was
reviewed and approved by the University of British
Columbia. Blood was obtained with appropriate consent.
Fifty pairs of monozygotic discordant twins (100 samples
in total, 35 female and 15 male pairs) were chosen for
analysis. The clinical data for the MS patients is shown in
Table 1. The average age at blood sampling was 41.1 years
(standard deviation = 3.7 years). 31 (62%) twin pairs were
HLA-DRB1*15 positive.
CpG Dinucleotide Prediction
The sequence of the pIV promoter from the NCBI Build
36.1 reference sequence was analysed to identify CpG
islands that could be methylated. The methodology for
this is described in [17].
Sequencing of promoter pIV
Total genomic DNA was extracted from whole blood as
part of the CCPGSMS. PCR was performed using the prim-
ers shown in Table 2 under standard conditions [18] with
an annealing temperature of 60 degrees Celsius and using
AmpliTAQ gold (Applied Biosystems), yielding a PCR
amplicon 257 base pairs in size. Sequencing reactions
were carried out using BigDye v3.1 after which the DNA
was sequenced using an ABI 3700 automated sequencer.
Bisulfite treatment and Methylation Specific PCR
Genomic DNA was treated using methylSEQr Bisulfite
Conversion Kit from Applied BioSystems, following the
manufacturer's protocol. This converts unmethylated
cytosines to uracils and leaves methylated cytosines
unchanged. Methylation specific PCR [19], using methyl-
ated DNA and unmethylated DNA specific primer sets was
performed on treated DNA to detect methylation of the
CpG island in the MHC2TA promoter. PCR was per-
Table 2: Primer sequences used for sequencing
Primers
Forward Primer GGTTGGACTGAGTTGGAGAGA
Reverse Primer GGAGCAACCAAGCACCTACT
Table 1: Clinical details of MS patients
Clinical/demographic details
Sample Size (n) 50
Mean age of onset (years) 31.1
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formed using the primers shown in Table 3 under stand-
ard conditions [18] with an annealing temperature of
55.5 degrees Celsius. Each PCR was performed twice for
each sample to ensure validity of results. Universal meth-
ylated DNA, universal unmethylated DNA (both from
CpGenome™) and water was used as positive, negative
and blank controls respectively. Amplified fragments were
confirmed by a 2.0% agarose gel.
Results
In silico prediction of CpG islands in the pIV promoter
uncovered 1 potential site (Figure 1) Sequencing of the
region did not identify any polymorphisms in the pIV
promoter sequence in any of the twin pairs.
Methylation specific PCR was able to distinguish between
methylated and unmethylated control samples (Figure 2).
All twin DNA samples produced amplicons only with the
unmethylated DNA specific primers.
Discussion
Multiple sclerosis is unambiguously associated with the
MHC class II region [6] and this locus exerts the strongest
genetic effect on the risk of developing the disease [4].
MHC2TA is the master regulator of MHC class II gene
expression and therefore variability at the MHC2TA gene
could conceivably influence susceptibility to MS.
In this investigation we studied the sequence variability of
the pIV promoter of the MHC2TA gene and found no var-
iation. This is in agreement with previous studies and this
conservation may be a result of the importance of this
promoter to gene function.
The only known epigenetic modification of DNA in mam-
mals is methylation of cytosine at position C5 in CpG
dinucleotides [20]. DNA methylation affects transcription
directly, by influencing the binding of specific transcrip-
tion factors, and indirectly, by recruiting methyl-CpG-
binding proteins and their associated chromatin remode-
ling activities. It has been shown that methylation of the
pIV promoter can influence MHC2TA  expression.
Monozygotic twins share a common genotype. However,
genetically identical twin pairs exhibit differences in sus-
ceptibility to many diseases, including MS, where the
monozygotic twin concordance rate at its highest does not
exceed 30% [21]. There are several possible explanations
for these observations, one of these being the existence of
epigenetic differences. In this study, we used a cohort of
monozygotic MS discordant twins to examine whether
methylation differences of the MHC2TA promoter could
explain differences in susceptibility to disease. We did not
detect methylation of CpG dinucleotides in the pIV pro-
moter in any of our samples, either MS affected or not.
Although this study argues against a role of methylation of
MHC2TA in MS disease pathogenesis, it must be remem-
bered that whilst genomic information is uniform among
the different cells of a complex organism, the epigenome
varies from tissue to tissue, controlling the differential
expression of genes and providing specific identity to each
cell type. Hence, by looking solely at peripheral blood
mononuclear cells we may have missed tissue specific
methylation of the MHC2TA promoter. Furthermore, a
recent study which compared global and locus specific
methylation patterns in monozygotic twins, showed that
although indistinguishable in early life, epigenetic pro-
files of monozygotic twins change with age [22] and
hence for an adult onset disease with susceptibility deter-
Table 3: Primer sequences used for methylation specific PCR
Primers Sequence Product Size
Methylated Forward TGTTTGGTTGTTTTATAGTTTGGTTC 60 bp
Methylated Reverse CTACTAATAACCTCTCCCTCCCG
Unmethylated Forward TTGGTTGTTTTATAGTTTGGTTTGA 157 bp
Unmethylated Reverse CTACTAATAACCTCTCCCTCCCAC
Predicted CpG island in the MHC2TA gene promoter IV Figure 1
Predicted CpG island in the MHC2TA gene promoter IV.BMC Medical Genetics 2008, 9:63 http://www.biomedcentral.com/1471-2350/9/63
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mined early in life [23,24] timing of any epigenetic
changes may be crucial, and our study may not have been
able to detect methylation of MHC2TA at an early age that
has since decayed. Additionally, we may have missed low
level methylation patterns and it would be necessary to
examine every CpG dinucleotide of MHC2TA to be confi-
dent that an association between methylation and disease
had not been missed just because the wrong markers had
been typed.
Conclusion
In summary, although our results do not completely rule
out the possibility of an association between methylation
of MHC2TA and MS we believe that our data is sufficient
to exclude a major effect of methylation of this gene in MS
pathology.
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